Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05479578 · ClinicalTrials.gov registry record · Phase 1
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
A Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Adenocarcinoma, sponsored by Rashmi Verma, MD.
- Active
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT05479578: Active Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Adenocarcinoma, sponsored by Rashmi Verma, MD.
NCT05479578 is a Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Adenocarcinoma that is active but no longer recruiting, run by Rashmi Verma, MD. The registered enrollment target is 7 participants, below the 78-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05479578, a Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by Rashmi Verma, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving low doses of cyclophosphamide daily may reduce side effects. Dexamethasone is a corticosteroid drug that is used to treat some of the problems caused by chemotherapy treatment. The combination of cyclophosphamide and dexamethasone may work better in treating patients with castration resistant prostate cancer.
Primary Outcome
Feasibility, defined as \>= 80% of participants completing treatment, and safety as defined by Grade 3 or higher adverse events (AEs) observed per National Cancer Institute (NCI) Common Terminology Criteriafor Adverse Events (CTCAE 5.0) criteria
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
Study Locations (1)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 1 |
What the registry record for NCT05479578 still lists
NCT05479578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 78-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT05479578 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05479578 about?
NCT05479578 is a clinical study titled "Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer". This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide, work in different ways to ...
What is the current status of trial NCT05479578?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-06-29. Estimated completion is 2025-05-01.
What conditions does trial NCT05479578 study?
This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8.
What interventions are being tested in trial NCT05479578?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT05479578?
This trial is sponsored by Rashmi Verma, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05479578 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castration-Resistant Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05479578's enrollment target sits among peer trials
7 42nd of 43 higher than 1 of 43 other Castration-Resistant Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Castration-Resistant Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
RECRUITING · Phase 1
-
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
RECRUITING · Phase 1
-
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using 18F-TRX
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI